291 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over … reasonably be expected to provide a basis for the FDA to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who … to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities.” Neither the Company nor any of its Subsidiaries nor, to the Knowledge
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have … statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA to invoke its policy with respect to “Fraud
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have … statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA to invoke its policy with respect to “Fraud
8-K
EX-3.1
cj8vo
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-1.1
8mvn2e
5 May 23
Entry into a Material Definitive Agreement
5:15pm